Literature DB >> 12458098

Re: nebulized furosemide for dyspnea in terminal cancer patients.

Paddy Stone, Anna Kurowska.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12458098     DOI： 10.1016/s0885-3924(02)00479-7

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  4 in total

Review 1.  Dyspnea review for the palliative care professional: treatment goals and therapeutic options.

Authors:  Arif H Kamal; Jennifer M Maguire; Jane L Wheeler; David C Currow; Amy P Abernethy
Journal:  J Palliat Med       Date:  2012-01       Impact factor: 2.947

2.  Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness.

Authors:  Capucine Morélot-Panzini; Carl R O'Donnell; Robert W Lansing; Richard M Schwartzstein; Robert B Banzett
Journal:  Respir Physiol Neurobiol       Date:  2017-10-12       Impact factor: 1.931

3.  Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.

Authors:  Robert W Hallowell; Richard Schwartzstein; Carl R O'Donnell; Andrew Sheridan; Robert B Banzett
Journal:  Lung       Date:  2019-11-15       Impact factor: 2.584

4.  An online survey of Australian physicians reported practice with the off-label use of nebulised frusemide.

Authors:  Phillip J Newton; Patricia M Davidson; Christine Sanderson
Journal:  BMC Palliat Care       Date:  2012-04-30       Impact factor: 3.234
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.